Abstract
ACE inhibitors have established their role in the management of hypertension as well as in the primary and secondary prevention of cardiovascular events. Furthermore, they have proven their role in delaying the worsening of renal function in patients with chronic renal disease.
Over the last few years their use to prevent the new onset of diabetes has come to the forefront. Post-hoc analyses of large mutli-center clinical trials such as the Captopril Prevention Project and the Heart Outcomes Prevention Evaluation have suggested that their use may delay or prevent the onset of diabetes. However many of these results are based on secondary analyses and few prospective clinical trials exist. In the two prospective trial so far conducted regarding the use of ACEi and ARB as a means to diabetes prevention the effects of these drugs compared to lifestyle modifications have been minimal and do not yet warrant their use to this effect.
While there is strong evidence for modulation the Renin-Angiotensin System in patients with hypertension, coronary heart disease and renal dysfunction the evidence for preventing diabetes remains scarce and will need to be investigated further.
Keywords: Diabetes, hypertension, RAS, ACEi, ARB, chronic renal disease, coronary heart disease, insulin, glucose transporter -4 protein, glycaemic control
Current Pharmaceutical Design
Title: Renin-Angiotensin-Aldosterone System Antagonists and the Prevention of Type 2 Diabetes Mellitus
Volume: 18 Issue: 7
Author(s): Nikolaus Marx
Affiliation:
Keywords: Diabetes, hypertension, RAS, ACEi, ARB, chronic renal disease, coronary heart disease, insulin, glucose transporter -4 protein, glycaemic control
Abstract: ACE inhibitors have established their role in the management of hypertension as well as in the primary and secondary prevention of cardiovascular events. Furthermore, they have proven their role in delaying the worsening of renal function in patients with chronic renal disease.
Over the last few years their use to prevent the new onset of diabetes has come to the forefront. Post-hoc analyses of large mutli-center clinical trials such as the Captopril Prevention Project and the Heart Outcomes Prevention Evaluation have suggested that their use may delay or prevent the onset of diabetes. However many of these results are based on secondary analyses and few prospective clinical trials exist. In the two prospective trial so far conducted regarding the use of ACEi and ARB as a means to diabetes prevention the effects of these drugs compared to lifestyle modifications have been minimal and do not yet warrant their use to this effect.
While there is strong evidence for modulation the Renin-Angiotensin System in patients with hypertension, coronary heart disease and renal dysfunction the evidence for preventing diabetes remains scarce and will need to be investigated further.
Export Options
About this article
Cite this article as:
Marx Nikolaus, Renin-Angiotensin-Aldosterone System Antagonists and the Prevention of Type 2 Diabetes Mellitus, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436557
DOI https://dx.doi.org/10.2174/138161212799436557 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Cancer, Pharmacokinetic and Biodistribution Studies of Cremophor EL Free Alternative Paclitaxel Formulation
Current Drug Safety Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) during Adolescent Brain Development
Current Psychopharmacology Meet Our Editorial Board Member
Current Medical Imaging Influence of Leptin on Immunity
Current Immunology Reviews (Discontinued) Exercise Prescription for Post-Menopausal Women with Obesity
Current Women`s Health Reviews Sex Differences and Emerging New Risk Factors for Atherosclerosis and Its Thrombotic Complications
Current Pharmaceutical Design The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Sorbitol Dehydrogenase: Structure, Function and Ligand Design
Current Medicinal Chemistry Membrane Rafts in the Respiratory System
Current Respiratory Medicine Reviews Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Cardiovascular & Hematological Agents in Medicinal Chemistry Exercise Induced Cardioprotection: An Overview of a Unique Form of Preconditioning
Current Cardiology Reviews Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Lappaconitine: Influence of Halogen Substituent on the Antiarrhythmic Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Development of Meat and Poultry Products Enriched with n-3 PUFAs and their Functional Role
Current Nutrition & Food Science Screening for Silent Coronary Artery Disease in Diabetics- or Not?
Current Diabetes Reviews Oxidative Damage Impact on Aging and Age-Related Diseases: Drug Targeting of Telomere Attrition and Dynamic Telomerase Activity Flirting with Imidazole-Containing Dipeptides
Recent Patents on Drug Delivery & Formulation Clinical Queries Addressed in Patients with Systemic Autoimmune Diseases. Can Cardiovascular Magnetic Resonance Give the Final Solution?
Inflammation & Allergy - Drug Targets (Discontinued) Dietary Agents for Prostate Cancer Chemoprevention: An Overview
Current Cancer Therapy Reviews